# Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

> **NCT03460743** · PHASE3 · COMPLETED · sponsor: **Laboratorios Liomont** · enrollment: 1556 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Study group - quadrivalent recombinant hemagglutinin influenza vaccine
- **BIOLOGICAL:** Control group - quadrivalent inactivated influenza vaccine

## Key facts

- **NCT ID:** NCT03460743
- **Lead sponsor:** Laboratorios Liomont
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2019-10-22
- **Final completion:** 2019-10-22
- **Target enrollment:** 1556 (ACTUAL)
- **Last updated:** 2019-11-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460743, "Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03460743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*